NYSEAMERICAN : MAIA

MAIA Biotechnology, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 1.14 USD (Oct 30, 2026, 10:29 AM EDT) · Market cap 69.34M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Details

NameMAIA Biotechnology, Inc.
SectorHealthcare
IndustryBiotechnology
Employees13
Founded2018
Ipo Date2022-07-28
CeoVlad Vitoc
CountryUnited States
ExchangeNYSEAMERICAN
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price5.00
IsinUS5526411021
Cusip552641102
Cik1878313
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Vlad Vitoc M.B.A., M.D.Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors
Jeffrey C. Himmelreich M.B.A.Head of Finance and Principal Financial and Accounting Officer
Dr. Sergei M. Gryaznov Ph.D.Chief Scientific Officer
Linda MoreiraCompany Secretary

Contact

Address444 West Lake Street, Suite 1700, Chicago, Illinois 60606, United States
Phone312 416 8592
Websitehttps://maiabiotech.com